Loading
A phase 1/2 trial of Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab and Obinutuzumab in non-Hodgkin lymphoma, run by BeOne Medicines, now recruiting.
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies is a phase 1/2 interventional study registered as NCT06634589 by BeOne Medicines, with 80 participants planned, started 2024-11-27 and due to reach its primary completion in 2028-12-02. Interventions recorded: Tacabrutideg, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab and Obinutuzumab.
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Sonrotoclax, Obinutuzumab, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Glofitamab, Obinutuzumab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Glofitamab, Obinutuzumab and the tag pipeline.